MRD testing is crucial for high-risk MM patients, aiding in early detection and treatment decisions, despite logistical and insurance barriers. Physicians primarily use MRD to monitor remission, ...
MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...
Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...
Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics. Testing for minimal residual disease ...
Medical Device Network on MSN
Roche builds MRD testing arsenal in $595M Saga Diagnostics buyout
Roche subsidiary, Foundation Medicine, is boosting its presence in the MRD testing space, which it touts as “one of the ...
Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...
The US Food and Drug Administration (FDA) has granted breakthrough device designation for Quest Diagnostics’ Haystack minimal residual disease (MRD) test for colorectal cancer. Haystack is designed to ...
Roche's Foundation Medicine will strengthen its testing portfolio by adding Saga's Pathlight tumor-informed molecular residual disease platform.
New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (DGX), a ...
SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
We estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results